Radiotherapy of the Excretable Radioactive Gold Nanocomposite with Intratumoral Injection

Lin, Fong-Sian; Chen, Chien‐Hung; Tseng, Fan‐Gang; Hwu, Y.; Chen, Jen‐Kun; Lin, Shu‐Yi; Yang, Chung‐Shi

doi:10.7763/ijmmm.2013.v1.56

Cited by 5 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, many MNPs may undergo in vivo surface degradation or even some forms of metabolism under the physiological conditions, prior to their disposition from the body. For example, in a study reported by Lin et al (2013), the HD of neutron‐activated 198 Au‐AuNPs nanocomposites increased from 2 to 60 nm after coating with gum arabic. The 198 Au‐Au/gum arabic nanocomposites were not expected to be seen upon urinary excretion because of their size being well above the renal clearance threshold.…”

Section: Pharmacokinetics Of Radiolabeled Mnpsmentioning

confidence: 97%

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Bahadori

Mulgaonkar

Hart

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Radiolabeled metal‐based nanoparticles (MNPs) have drawn considerable attention in the fields of nuclear medicine and molecular imaging, drug delivery, and radiation therapy, given the fact that they can be potentially used as diagnostic imaging and/or therapeutic agents, or even as theranostic combinations. Here, we present a systematic review on recent advances in the design and synthesis of MNPs with major focuses on their radiolabeling strategies and the determinants of their in vivo pharmacokinetics, and together how their intended applications would be impacted. For clarification, we categorize all reported radiolabeling strategies for MNPs into indirect and direct approaches. While indirect labeling simply refers to the use of bifunctional chelators or prosthetic groups conjugated to MNPs for post‐synthesis labeling with radionuclides, we found that many practical direct labeling methodologies have been developed to incorporate radionuclides into the MNP core without using extra reagents, including chemisorption, radiochemical doping, hadronic bombardment, encapsulation, and isotope or cation exchange. From the perspective of practical use, a few relevant examples are presented and discussed in terms of their pros and cons. We further reviewed the determinants of in vivo pharmacokinetic parameters of MNPs, including factors influencing their in vivo absorption, distribution, metabolism, and elimination, and discussed the challenges and opportunities in the development of radiolabeled MNPs for in vivo biomedical applications. Taken together, we believe the cumulative advancement summarized in this review would provide a general guidance in the field for design and synthesis of radiolabeled MNPs towards practical realization of their much desired theranostic capabilities. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Diagnostic Tools > Diagnostic Nanodevices Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Section: Pharmacokinetics Of Radiolabeled Mnpsmentioning

confidence: 97%

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Bahadori

Mulgaonkar

Hart

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Thus, due to the long penetration depth of the emitted electrons (≈0.05-12 mm), b emitters are regarded as the most suitable for the treatment of large or bulky tumors (7). b-Emitting radionuclides 198 Au, 199 Au, 131 I, and 177 Lu have been investigated as potential nanobrachytherapeutic agents (17,37,49,50). 198 Au was used in the initial works of radioactive collidal gold (60).…”

Section: Radionuclides For Nanobrachytherapymentioning

confidence: 99%

“…Even after 2 weeks of radioactive injection, 50% of the nanoparticles were found to be accumulated in the tumor and 8.9% in the liver. (49) b…”

Section: Ct26 Colorectal Cancersmentioning

confidence: 99%

Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy

et al. 2021

View full text Add to dashboard Cite

Interstitial brachytherapy (BT) is generally used for the treatment of well-confined solid tumors. One example of this is in the treatment of prostate tumors by permanent placement of radioactive seeds within the prostate gland, where low doses of radiation are delivered for several months. However, successful implementation of this technique is hampered due to several posttreatment adverse effects or symptoms and operational and logistical complications associated with it. Recently, with the advancements in nanotechnology, radioactive nanoparticles (radio-NPs) functionalized with tumor-specific biomolecules, injected intratumorally, have been reported as an alternative to seed-based BT. Successful treatment of solid tumors using radio-NPs has been reported in several preclinical studies, on both mice and canine models. In this article, we review the recent advancements in the synthesis and use of radio-NPs as a substitute to seed-based BT. Here, we discuss the limitations of current seed-based BT and advantages of radio-NPs for BT applications. Recent progress on the types of radio-NPs, their features, synthesis methods, and delivery techniques are discussed. The last part of the review focuses on the currently used dosimetry protocols and studies on the dosimetry of nanobrachytherapy applications using radio-NPs. The current challenges and future research directions on the role of radio-NPs in BT treatments are also discussed.

show abstract

“…They reported that the chitosan- 198 AuNPs with high radionuclide purity are produced using epithermal neutron-capture reaction, 197 Au (n, γ) 198 Au, are especially useful for cancer treatment and imaging. In another study reported by Lin et al, 47 a nanocomposite of gum arabic stabilized AuNPs (AuNPs@GA) was first synthesized by exposing the mixture of HAuCl 4 and GA solution under synchrotron X-ray. Then, the prepared GA-AuNPs was neutron-activated to generate radioactive GA- 198 AuNPs and evaluated with H460 tumor model (lung cancer) by intratumoral injection.…”

Section: Gold-198mentioning

confidence: 99%

An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions

Farzin¹,

Sheibani²,

Moassesi³

et al. 2018

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

Radiotherapy of the Excretable Radioactive Gold Nanocomposite with Intratumoral Injection

Abstract: Abstract

Cited by 5 publications

References 18 publications

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy

An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions

Contact Info

Product

Resources

About